RAF modulators and methods of use.
Exelixis claims a series of RAF kinase inhibitors based on a 3-oxo-2,3-dihydro-1H-isoindol-1-yl core structure. Both the chemical matter and the biochemical target appear to be new for Exelixis, and many examples have IC(50) values < 100 nM. These compounds are claimed to have the potential to treat diseases that are associated with uncontrolled, abnormal and/or unwanted cellular activities such as cancer.
Boyer
Stephen J
SJ
Bayer Pharmaceuticals Corp., 400 Morgan Lane, West Haven, CT 06516, USA.